Reevaluation of lock solutions for Central venous catheters in hemodialysis: a narrative review

Ren Fail. 2022 Dec;44(1):1501-1518. doi: 10.1080/0886022X.2022.2118068.

Abstract

Background: A significant proportion of incident and prevalent hemodialysis patients have central venous catheters for vascular access. No consensus is available on the prevention of catheter dysfunction or catheter-related bloodstream infections in patients undergoing hemodialysis by means of catheter lock solutions.

Method: We reviewed the effects of single and combined anticoagulants with antibacterial catheter lock solutions or other antimicrobials for the prevention of thrombosis or infections in hemodialysis patients. Relative risks with 95% confidence intervals for trials of the same type of catheter locking solution were pooled.

Sources of information: We included original research articles in English from PubMed, EMBASE, SpringerLink, Elsevier and Ovid using the search terms 'hemodialysis,' 'central venous catheter,' 'locking solution,' 'UFH,' 'low molecular weight heparin,' 'EDTA,' 'citrate,' 'rt-PA,' 'urokinase,' 'gentamicin,' 'vancomycin', 'taurolidine,' 'sodium bicarbonate,' 'hypertonic saline' and 'ethanol' and 'catheter'.

Findings: Low-dose heparin lock solution (< 5000 U/ml) can efficiently achieve anticoagulation and will not increase the risk of bleeding. Low-concentration citrate (< 5%) combined with rt-PA can effectively prevent catheter infection and dysfunction. Catheter-related infections may be minimized by choosing the appropriate antibiotic and dose.

Limitations: There is a lack of follow-up validation data for LMWH, EDTA, taurolidine, sodium bicarbonate, ethanol, and other lock solutions.

Implications: Since catheterization is common in hemodialysis units, studies on long-term treatment and preventative strategies for catheter dysfunction and catheter-related infection are warranted.

Keywords: Hemodialysis; antibiotic lock solutions; central venous catheter; tissue plasminogen activators.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anticoagulants / therapeutic use
  • Catheter-Related Infections* / microbiology
  • Catheterization, Central Venous*
  • Central Venous Catheters* / adverse effects
  • Citrates / adverse effects
  • Citric Acid
  • Edetic Acid
  • Heparin / therapeutic use
  • Heparin, Low-Molecular-Weight
  • Humans
  • Renal Dialysis / adverse effects
  • Sodium Bicarbonate

Substances

  • Anti-Bacterial Agents
  • Anticoagulants
  • Citrates
  • Heparin, Low-Molecular-Weight
  • Citric Acid
  • Sodium Bicarbonate
  • Heparin
  • Edetic Acid

Grants and funding

This work was supported by the National Natural Science Foundation of China under Grant 92049103.